Inovio Q3 net loss widens on non-cash warrant liabilities
Overview
Inovio Q3 2025 net loss widens to $45.5 mln, driven by non-cash warrant liabilities
Operating expenses decreased to $21.2 mln from $27.3 mln in Q3 2024
Outlook
Inovio projects cash will support operations into Q2 2026
Result Drivers
R&D EXPENSES - Decrease in R&D expenses due to lower costs for INO-3107 manufacturing and clinical studies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.87 | ||
Q3 Net Income | -$45.50 mln | ||
Q3 Operating Expenses | $21.20 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $7.50, about 71.7% above its November 7 closing price of $2.12
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.